DS

David Scadden

Board Member

Carisma Therapeutics

Roles

Board MemberatCarisma Therapeutics
Scientific FounderatMagenta Therapeutics

Carisma Therapeutics Pipeline

DrugIndicationPhase
CT-0508HER2-Overexpressing Solid TumorsPhase 1
CT-0525HER2-Positive Solid TumorsPreclinical
In Vivo CAR-MUndisclosed Oncology TargetsDiscovery
CT-1119GPC3+ Solid TumorsDiscovery/Preclinical
CT-2401Liver FibrosisDiscovery/Preclinical
Autoimmune Disease ProgramAutoimmune DiseaseDiscovery